Alerta

用于去除眼睛中的脂质积聚的纳米盘

Resumen de: AU2024231998A1

The present disclosure relates to methods of removing lipid (e.g., cholesterol) or preventing lipid accumulation in the eye of an individual (e.g., human) and methods of preventing or treating an eye disease characterized by lipid accumulation (e.g., age-related macular degeneration) in an individual, comprising administering to the eye of the individual an effective amount of a pharmaceutical composition comprising a plurality of nanodiscs, wherein the nanodisc comprises a membrane scaffold protein (MSP) and a phospholipid.

负载胶原靶向脂质体的硒纳米颗粒水凝胶及其制备方法与应用

Resumen de: CN121059510A

本发明提供了一种负载胶原靶向脂质体的硒纳米颗粒水凝胶及其制备方法与应用，属于生物医药技术领域。本发明首先合成了包封H‑151的脂质体，并在脂质体表面修饰一型胶原特异性结合肽(LHERHLNNN)，使得负载H‑151的脂质体具有肌腱靶向性，能够在年轻TDSCs周围大量蓄积，增强给药效率。另一方面，本发明以接枝苯硼酸的透明质酸为封盖剂合成硒纳米颗粒(HPSe)，再将硒纳米颗粒与聚乙烯醇反应成胶(PVA/HASe)，兼具ROS响应性和可注射性，同时负载包封H‑151的TDSCs靶向性脂质体，形成水凝胶复合体系。本发明的水凝胶复合体系通过抗衰老、抗炎、免疫调控协同作用，达到了维持衰老肌腱的内稳态，最终促进了肌腱病的修复，为衰老肌腱病的修复提供了一种有效的治疗策略。

用于制备各种尺寸的脂质纳米颗粒的微流体设备及使用该微流体设备的制备方法

Resumen de: WO2025155087A1

The present invention relates to a microfluidic device for preparing lipid nanoparticles that can deliver nucleic acids, and a lipid nanoparticle preparation method using same. By using the microfluidic device, lipid nanoparticles of a desired size can be prepared by adjusting the molar ratio between compositions and the Reynolds number.

microRNA 244-5P抑制剂在制备治疗脓毒症心肌病的产品中的应用

Resumen de: CN121059629A

本申请涉及药物制备技术领域，尤其涉及一种microRNA244‑5P抑制剂在制备治疗脓毒症心肌病的产品中的应用。其中，microRNA 244‑5P抑制剂在制备治疗脓毒症心肌病的产品中的应用，microRNA 244‑5P抑制剂的序列如Seq.ID No.1所示。提供的microRNA 244‑5P抑制剂，为靶向治疗脓毒症心肌病奠定了精准基础。该抑制剂能特异性识别并作用于相关靶点，精准干预脓毒症心肌病的病理进程，具有更稳定的结构和活性，可确保在制备治疗产品时，能持续、高效地发挥抑制作用，为后续产品的研发、生产和质量控制提供了明确的物质基础和技术依据，极大提高了治疗的针对性和有效性。

HA包被高多不饱和脂肪酸蛋黄磷脂-木犀草素脂质体复合物

Resumen de: CN121059566A

本发明提供了一种HA包被高多不饱和脂肪酸蛋黄磷脂‑木犀草素脂质体复合物，所述复合物以高多不饱和脂肪酸蛋黄磷脂为基质形成脂质体，木犀草素封装于该脂质体的疏水核心中，同时，在所述脂质体的表面以透明质酸HA为包被层，显著提升了木犀草素的包封率(EE)和脂质体的稳定性。实验表明，当HA浓度为1.00mg/mL时，EE达91.32±0.66％，较未包被脂质体(63.62±1.23％)显著提高。HA涂层通过填充脂质体间隙、增强静电排斥及抑制脂质氧化，有效减少木犀草素泄漏，延缓储存过程中的粒径增长(4℃下28天仍保持均匀分散)，并改善缓释性能(胃肠阶段释放率较未包被脂质体降低20％以上)。此外，HA涂层显著降低脂质氧化水平，适用于口服递送系统及抗氧化功能产品开发。

用于生产植物源纳米囊泡的方法及其应用

Resumen de: WO2024223549A1

The present invention concerns a method for the production, purification, and stabilization of plant-derived nanovesicles. It also concerns a composition containing the nanovesicles obtained by this method for hypocholesterolemic, hypoglycemic, hypolipidemic, anti-ageing, and antioxidant use.

一种可缓释药物的水凝胶微针护理敷料及其制备方法

Resumen de: CN121059501A

本发明涉及医用材料技术领域，具体公开了一种可缓释药物的水凝胶微针护理敷料及其制备方法。一种可缓释药物的水凝胶微针护理敷料，包括水凝胶基底，规则附着在水凝胶基底面向皮肤一侧的微针，以及附着在水凝胶基底背向皮肤一侧的透气膜层，微针阵列的针尖区域填充有靶向缓释载药纳米粉末。该靶向缓释载药纳米粉末可实现病灶微环境响应的按需给药，同时形成基础缓释平台，清除病灶部位过量的活性氧，保护药物活性，从而延长药物释放时间，提高抑菌效率。

一种抗肝癌HLA-A*11型疫苗及其制备方法和应用

Resumen de: CN121064279A

本发明公开了一种抗肝癌HLA‑A*11型疫苗及其制备方法和应用。本发明mRNA疫苗包含序列由SEQ ID NO：32所示的DNA转录的mRNA；本发明首先通过筛选得到序列如SEQ ID NO：1～14所示的新抗原靶点，将其改造后的氨基酸序列用于构建mRNA，再利用微流控技术制备mRNA‑脂质纳米颗粒，将疫苗药效成分包裹于脂质纳米颗粒中，有助于将病毒蛋白转运到细胞中，并保护其免受破坏性酶的侵害。本发明提供的mRNA肿瘤疫苗，是一种包含肿瘤可变剪接的超大范围广谱抗原，并且其是严格按照患者HLA‑A*11:01分型(包含其他HLA‑A*11分型)设计的高覆盖度、高免疫原性肿瘤新生抗原的mRNA疫苗。

用于矫正眼睛状况的系统、方法和材料组合物

Resumen de: WO2024201468A1

Methods, kits and material composition for use in correction of eye condition are disclosed. This includes a selected three-dimensional patterning on the surface of a cornea of a user. The pattern is selected to provide an optical effect in accordance with a predetermined vision impediment of the user. A dispersion, in the form of a liquid (aqueous solution) comprising nanoparticles, is applied onto said selected three- dimensional pattern such that the nanoparticles are dispersed in incision regions of the pattern. The nanoparticles comprise biocompatible protein based nanoparticles. The dispersion may be used as eye drops thereby allowing the nanoparticles to occupy the etching regions on the cornea, thereby functionalizing and maintaining the visual correction effect of eye condition by said pattern. The present disclosure further provides a method and a kit for ablating the corneal tissue in a selected pattern by using a visual spectrum illumination.

一种脂质纳米颗粒及其应用、药物递送载体

Resumen de: CN121059567A

本发明属于生物医药领域，具体涉及一种脂质纳米颗粒及其应用、药物递送载体。该脂质纳米颗粒包括可电离脂质、胆固醇、磷脂、聚乙二醇化脂质、固醇替代物，其特征在于：所述可电离脂质为Lipid 5，所述磷脂为DSPC，所述聚乙二醇化脂质为18:0 mPEG2000 PE，所述固醇替代物为β‑谷甾醇、豆甾醇或豆甾烷醇或其衍生物中的一种或多种；可电离脂质：胆固醇：磷脂：聚乙二醇化脂质：固醇替代物的摩尔比为40‑60：5‑38.5：5‑30：1‑2：5‑38.5。本发明通过各组分间高度协同，构建了具备独特理化特性的LNP，克服了现有技术对造血干祖细胞递送效率低、特异性差的技术难题，实现了体内外对HSPCs高效率、高特异性的药物递送。本发明还提供了包含该脂质纳米颗粒的药物递送载体及制备方法。

一种靶向巨噬细胞的IRG1过表达纳米系统及其制备方法和应用

Resumen de: CN121059564A

本发明公开了一种靶向巨噬细胞的IRG1过表达纳米系统及其制备方法和应用。所述纳米系统包括IRG1过表达质粒、普鲁士蓝纳米囊泡和巨噬细胞膜，所述IRG1过表达质粒包埋于所述普鲁士蓝纳米囊泡内，所述巨噬细胞膜包覆于所述普鲁士蓝纳米囊泡外部。并经过一系列体内外实验验证，本发明Ma(PB@IRG1)纳米系统能够靶向炎性巨噬细胞和炎症区域，发挥免疫‑代谢双重调控，达到逆转炎症、恢复代谢功能、改善肥胖等作用，为有效治疗2型糖尿病提供了新的治疗选择，具有重要的临床转化潜力。

一种刺突蛋白嵌合的仿生细胞膜纳米囊泡和具有抗癌活性的纳米囊泡

Resumen de: CN121064291A

本发明属于生物医学工程材料领域，具体涉及一种刺突蛋白嵌合的仿生细胞膜纳米囊泡和具有抗癌活性的纳米囊泡。本发明提供了如SEQ ID NO.1所示的刺突蛋白。并进一步提供了表达该刺突蛋白纳米囊泡及其制成的负载有活性成分的基因工程化纳米囊泡。本发明提供的刺突蛋白及纳米囊泡能够靶向肿瘤细胞，能够诱导膜融合过程，有利于活性成分的递送，因此其制成的基因工程化纳米颗粒对于肿瘤具有更好的治疗效果。此外，本发明的刺突蛋白还可以广泛应用于肿瘤诊断、基因编辑、mRNA递送、大分子物质递送和肿瘤免疫治疗，具有广泛的应用前景。

一种靶向ASGR1的siRNA、递送系统及其应用

Resumen de: CN121065177A

本发明公开了一种靶向ASGR1的siRNA、递送系统及其应用。所述siRNA经过针对ASGR1靶点的特异性设计与筛选，可高效沉默ASGR1基因表达。同时，本发明构建了相应的用于siRNA递送的脂质纳米颗粒(LNP)，其创新性地采用胆汁酸部分替代传统LNP中的胆固醇组分。相较于常规LNP，该修饰显著提升了siRNA的递送效率，并明显增强了肝细胞对纳米颗粒的摄取能力，最终可有效改善肝脏脂质沉积。

ACA49过表达试剂和/或SOX9表达抑制剂在制备肝癌治疗药物中的应用

Resumen de: CN121059844A

本发明属于生物医疗技术领域，具体涉及ACA49过表达试剂和/或SOX9表达抑制剂在制备肝癌治疗药物中的应用。本发明通过实验验证可以得知，将ACA49过表达试剂和/或SOX9表达抑制剂注射至肝癌细胞肿瘤小鼠体内，可以显著抑制小鼠的肝癌肿瘤细胞数量以及肿瘤的生长，且对小鼠脏器无明显影响，安全性高。

新規な脂質化合物及びそれを含む脂質ナノ粒子組成物

Resumen de: US2024226287A1

The present disclosure relates to a novel lipid compound and a lipid nanoparticle composition including the same and, more specifically, the lipid nanoparticle composition includes ionized lipid, helper lipid, PEG-lipid, and additives, and may mitigate changes and side effects in the delivery mechanism and enhance the protein expression efficiency by including a biofriendly vitamin-based novel lipid compound and helper lipids including neutral lipids.

THERMORESPONSIVE HYDROGEL CONTAINING METAL-ORGANIC FRAMEWORK PARTICLES FOR NONINVASIVE OCULAR DRUG DELIVERY

Resumen de: US2025367130A1

A composition that includes agent-loaded metal-organic framework nanoparticles dispersed within a thermoresponsive hydrogel, wherein the agent is an agent for treating an ocular condition and the composition is configured for sustained topical ocular release.

LIPID COMPOUNDS, COMPOSITIONS, AND USES THEREOF

Resumen de: WO2025250729A1

The present disclosure provides lipid compounds and compositions (e.g., lipid nanoparticle (LNP) compositions) comprising lipid compounds of the present disclosure. The present disclosure provides methods of delivering an active agent (e.g., polynucleotide) to a cell or tissue in a subject, preferably an extrahepatic cell or tissue, comprising administering to the subject an effective amount of a lipid nanoparticle of the present disclosure, wherein the lipid nanoparticle comprises lipid compounds of the present disclosure and the active agent (e.g., polynucleotide).

Lipid Compounds and Uses Thereof

Resumen de: US2025367129A1

Compounds are provided having the following structure: (I) or a pharmaceutically acceptable salt, N-oxide, tautomer or stereoisomer thereof, wherein R1, G1, W and m, n, o and p are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a nucleic acid, compositions comprising the compounds and methods for their use and preparation are also provided.

BIODEGRADABLE LIPIDOIDS AND COMPOSITIONS AND METHODS OF USE THEREOF FOR LIVER TARGETED DELIVERY

Resumen de: US2025367128A1

Described are biodegradable lipid nanoparticles (LNPs) comprising biodegradable lipidoids and compositions thereof. In various embodiments, the LNP selectively targets a liver cell. In other aspects, the present invention relates to methods for in vivo delivery of therapeutic nucleic acids to the liver to prevent or treat diseases or disorders using the LNP compositions of the invention.

NANOPARTICLES AND NANOGEL DRUG COMPOSITIONS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION

Resumen de: US2025367118A1

Disclosed are nanoparticles and nanogel drug compositions and the use thereof for treating age-related macular degeneration.

COMPOSITIONS AND METHODS FOR DELIVERY OF OCULAR THERAPEUTICS

Resumen de: US2025367110A1

Compositions for treating ocular disease are disclosed herein. In some embodiments, the composition comprises a dynamic hydrogel comprising a polymer and a plurality of nanoparticles, wherein the polymer is non-covalently crosslinked with the plurality of nanoparticles. The dynamic hydrogel can also comprise an ocular therapeutic encapsulated by the dynamic hydrogel.

FOLIC ACID-MODIFIED LIPOSOME-ENCAPSULATED TILIANIN NANOCRYSTAL (FA-Lipo@Til NC), PREPARATION METHOD AND USE THEREOF

Resumen de: US2025367227A1

A folic acid-modified liposome-encapsulated tilianin nanocrystal (FA-Lipo@Til NC), and a preparation method and use thereof are provided. The FA-Lipo@Til NC includes a tilianin nanocrystal (Til NC) composition and a folic acid-modified phospholipid (FA-Lipo) bilayer encapsulated on a surface of the Til NC; where raw materials of the FA-Lipo bilayer include phospholipid, cholesterol (Chol), a methoxy poly(ethylene glycol)-cholesterol conjugate (mPEG-Chol), and a folic acid (FA) compound. The FA-Lipo@Til NC has a high drug loading capacity and a desirable stability. The inhibition of a Til dissolution behavior improves a penetration efficiency of the Til NC composition in intestinal mucus and an affinity with intestinal epithelial cells, thus effectively improving bioavailability of the Til.

MEDICAL HYDROGEL CONTAINING ULTRASONICALLY-IMAGEABLE BUBBLE MICROSPHERES AND PREPARATION METHOD THEREOF

Resumen de: US2025367331A1

Provided are a medical hydrogel containing ultrasonically-imageable bubble microspheres and a preparation method thereof. The medical hydrogel containing the ultrasonically-imageable bubble microspheres is formed by in-situ crosslinking of a polyethylene glycol precursor solution and a poly-amino crosslinker solution containing bubble microspheres, the polyethylene glycol precursor solution consisting of a multi-arm polyethylene glycol derivative and a buffer solution A.

ALBUMIN NANOCOMPOSITE COMPRISING PHYTOCHEMICAL AND COMPOSITION FOR IMPROVING MUSCLE DISEASE CONTAINING SAME

Resumen de: US2025367305A1

The present disclosure relates to an albumin nanocomposite comprising a phytochemical and a composition for muscle disease comprising the same, and more specifically, to an albumin nanocomposite comprising a phytochemical that exhibits an effect of inhibiting muscle loss caused by oxidative stress or inflammatory response and promoting the differentiation of myoblasts into muscle cells. The albumin nanocomposite comprising the phytochemical effectively delivers the phytochemical by targeting immune cells that induce reactive oxygen species and inflammatory responses. Accordingly, by regulating muscle-loss signaling pathways induced by reactive oxygen species and inflammatory responses, the nanocomposite inhibits muscle cell atrophy and promotes differentiation. Therefore, a composition comprising the albumin nanocomposite comprising the phytochemical according to the present disclosure can be provided as a composition for improving, preventing, or treating muscle diseases.

LIPID NANOPARTICLE FOR RADIATION THERAPY, MANUFACTURING METHOD, COMBINATION COMPOSITION, AND KIT

Nº publicación: US2025367333A1 04/12/2025

Solicitante:

KK TOSHIBA [JP]
KABUSHIKI KAISHA TOSHIBA

Resumen de: US2025367333A1

According to one embodiment, a radiotherapy lipid nanoparticle includes a biodegradable lipid nanoparticle, and a radioactive material as an active ingredient. The radioactive material is bound to the biodegradable lipid nanoparticle and located outside of the biodegradable lipid nanoparticle.